Reducing pancreatitis risk in patients with hypertriglyceridemia.
作者信息
MacDonald Blair J, Garrison Scott R, Turgeon Ricky D
机构信息
Research Coordinator in the Faculty of Pharmaceutical Sciences at the University of British Columbia in Vancouver.
Professor in the Department of Family Medicine at the University of Alberta in Edmonton.
出版信息
Can Fam Physician. 2023 Dec;69(12):849. doi: 10.46747/cfp.6912849.
Abstract
摘要
相似文献
1
Reducing pancreatitis risk in patients with hypertriglyceridemia.
Can Fam Physician. 2023 Dec;69(12):849. doi: 10.46747/cfp.6912849.
2
Prevention of recurrent acute pancreatitis in patients with severe hypertriglyceridemia: value of regular plasmapheresis.
Pancreas. 1996 Jul;13(1):96-9. doi: 10.1097/00006676-199607000-00013.
3
Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia.
N Engl J Med. 2024 Feb 1;390(5):476-477. doi: 10.1056/NEJMc2306575.
4
Management of Hypertriglyceridemia Induced Acute Pancreatitis.
Biomed Res Int. 2018 Jul 26;2018:4721357. doi: 10.1155/2018/4721357. eCollection 2018.
5
Severe hypertriglyceridemia-related acute pancreatitis.
Ther Apher Dial. 2013 Apr;17(2):130-7. doi: 10.1111/1744-9987.12008. Epub 2013 Feb 28.
6
Heparin and insulin for hypertriglyceridemia-induced pancreatitis: case report.
ScientificWorldJournal. 2009 Nov 1;9:1230-2. doi: 10.1100/tsw.2009.142.
7
[Acute pancreatitis and hypertriglyceridemia].
Rev Med Chil. 1989 Mar;117(3):315-21.
8
Hypertriglyceridemia-Associated Pancreatitis: New Concepts and Potential Mechanisms.
Clin Chem. 2023 Oct 3;69(10):1132-1144. doi: 10.1093/clinchem/hvad094.
9
Drug treatment of asymptomatic hypertriglyceridemia to prevent pancreatitis: where is the evidence?
Ann Intern Med. 2012 Nov 6;157(9):662-4. doi: 10.7326/0003-4819-157-9-201211060-00011.
10
Approach to patients with hypertriglyceridemia.
Best Pract Res Clin Endocrinol Metab. 2023 May;37(3):101659. doi: 10.1016/j.beem.2022.101659. Epub 2022 Apr 11.
本文引用的文献
1
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews.
Can Fam Physician. 2023 Oct;69(10):701-711. doi: 10.46747/cfp.6910701.
2
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5.
3
Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study.
Cardiovasc Diabetol. 2022 Jun 9;21(1):102. doi: 10.1186/s12933-022-01525-5.
4
Prevalence, severity and management of hypertriglyceridemia-associated pancreatitis; A 7-year retrospective cohort study at Canadian quaternary care hospitals.
J Clin Lipidol. 2022 Jul-Aug;16(4):455-462. doi: 10.1016/j.jacl.2022.05.064. Epub 2022 May 21.
5
Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.
J Clin Endocrinol Metab. 2012 Sep;97(9):2969-89. doi: 10.1210/jc.2011-3213.
6
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis.
JAMA. 2012 Aug 22;308(8):804-11. doi: 10.1001/jama.2012.8439.
7
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.
Lancet. 2010 May 29;375(9729):1875-84. doi: 10.1016/S0140-6736(10)60656-3. Epub 2010 May 10.
8
Statin use and risk of gallstone disease followed by cholecystectomy.
JAMA. 2009 Nov 11;302(18):2001-7. doi: 10.1001/jama.2009.1601.
9
Gallbladder disease as a side effect of drugs influencing lipid metabolism. Experience in the Coronary Drug Project.
N Engl J Med. 1977 May 26;296(21):1185-90. doi: 10.1056/NEJM197705262962101.
Zotero 插件